Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Retained Earnings (2016 - 2025)

Protalix BioTherapeutics (PLX) has 15 years of Retained Earnings data on record, last reported at -$378.4 million in Q4 2024.

  • For Q4 2024, Retained Earnings rose 0.83% year-over-year to -$378.4 million; the TTM value through Dec 2024 reached -$378.4 million, up 0.83%, while the annual FY2024 figure was -$378.4 million, 0.83% up from the prior year.
  • Retained Earnings reached -$378.4 million in Q4 2024 per PLX's latest filing, up from -$381.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$347.4 million in Q4 2020 and bottomed at -$389.9 million in Q4 2022.
  • Average Retained Earnings over 5 years is -$374.4 million, with a median of -$378.4 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: dropped 7.94% in 2021, then increased 2.13% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$347.4 million in 2020, then fell by 7.94% to -$374.9 million in 2021, then decreased by 3.98% to -$389.9 million in 2022, then increased by 2.13% to -$381.5 million in 2023, then increased by 0.83% to -$378.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$378.4 million in Q4 2024, -$381.5 million in Q4 2023, and -$389.9 million in Q4 2022.